Group items tagged

The Department of Health and Social Care (DHSC) has notified pharmacies over the shortage of Buserelin (Suprefact) 5.5mg/5.5ml solution for injection vials is out of stock until mid-August 2022. Limited supply of Buserelin (Suprefact) 5.5mg/5.5ml solution for injection vials remains available in NHS Trusts and health boards. Buserelin (Suprecur) 5.5mg/5.5ml solution for injection vials are currently available, however, this stock is short dated (expires end of July) and further stock is expected mid-August 2022. Buserelin (Suprecur)150microgram/dose nasal spray is out of stock until late-December 2022. Limited supply remains available in NHS Trusts and Health Boards. Nafarelin (Synarel) 200microgram/dose nasal spray remains available but is currently unable to support an uplift in demand (until mid-August 2022 when it can support a partial uplift in demand).

Supply of all Champix products, used for smoking cessation, will remain out of stock until further notice from the Medicines and Healthcare products Regulatory Agency (MHRA). The announcement follows a medicine recall order initiated by the MHRA for "all strengths of Champix® tablets" on October 14, 2021 at pharmacy and wholesaler level. Pfizer, the sole supplier of Champix tablets, stopped the distribution of 0.5mg and 1mg tablets in early June 2021. The company is currently unable to confirm when supplies will resume amid global regulatory investigations relating to the presence of nitrosamine impurities above the Pfizer's acceptable level of daily intake in several lots.

The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million from their budgets annually for the next five years due to the spiralling tax rates. The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said in its white paper released on Monday (October 30). The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets. BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars annually - a consequence of reduced competition.

People are advised to be prepared and order their repeat prescriptions in time so that they don't run out of their routine medicines over the Christmas and New Year break when services are likely to be busier than normal. As GP practices will be closed over the bank holidays and only some pharmacies will remain open, local NHS leaders have urged patients to plan ahead to avoid making last-minute requests for collecting repeat prescriptions, which can add avoidable pressure for doctors, pharmacies, and other NHS services. Sati Ubhi, Chief Pharmacist at NHS Cambridgeshire & Peterborough, have cautioned patients that running out of their usual medication can have serious consequences. "By ordering medicines as soon as possible, it allows enough time for it to be processed and dispensed and helps avoid a last-minute rush," she told Fenland Citizen.

E-pharmacy, a digital platform also known as internet pharmacy or online pharmacy, has emerged as an escape route to longstanding queues at pharmacy stores across almost all regions of the world, especially during the Covid-19 health crisis realm. They have long been recognised to act promptly in public health response, like ensuring an effective medicine supply system, resolving and monitoring drug shortage issues, educating about the proper use of PPE, promoting remote pharmacy services, and conducting drug evaluation and active surveillance. These factors will support in easing the load on healthcare facilities during the ongoing pandemic, eventually adding value to patients and the healthcare system. Overall, the e-pharmacy market size is expanding in terms of valuation on the back of regulations and standards laid by the respective governments. As per a recent study by Global Market Insights, the global e-pharmacy industry accounted for a business share of $68 billion in 2021 with an anticipated growth rate of 16.8 per cent through 2028.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on Wednesday (14 June). It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg tablets are out of stock until mid-July 2023. However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand. "Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC. "Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."

A survey of over six thousands pharmacies has revealed that the community pharmacy sector is buckling under growing cost and capacity pressures. The survey conducted by the Pharmaceutical Services Negotiating Committee, which also involved two thousand community pharmacy confirms, rising costs, patient demand and medicine supply issues continue to grip the sector. PSNC's 2023 Pharmacy Pressures Survey, run as a follow up to the 2022 pressures survey, provides clear comparative data showing the worsening situation across the sector. Govt must act now The result of the survey indeed paints a bleak picture for community pharmacies and it is clear that without urgent action from government and the NHS this will only get worse: more community pharmacies will either be forced to reduce the number of services they provide or, in the worst-case scenario, will be left with no option but to close their doors for good. The PSNC has urged the government to act now "to save our pharmacies, before it is too late for patients, the public, and the rest of the NHS". "This year's survey clearly shows that community pharmacies are buckling under growing cost and capacity pressures," said PSNC Chief Executive Janet Morrison.

Recently, the English Health Secretary has talked about introducing a 'Pharmacy First' model similar to that which exists in Scotland. This would be a win-win outcome providing people with better access to essential healthcare support, advice and treatment whilst relieving strain on other parts of the NHS, not least GPs and A&E. It is a no-brainer and yet despite a few media headlines there are still no firm proposals on the table to make this a reality. It surely cannot be right that you can receive a broad range of patient care services in Scotland which are not available in England. It works well in Scotland, Wales is keen to develop more pharmacy-based services and Northern Ireland, leaving aside the current funding dispute, has had a minor ailments service for many years. If the English Health Secretary is sincere in his interest in adopting an English version of the Scottish model, then there are critical aspects he needs to consider. Firstly, start with the patient journey through the healthcare ecosystem from illness prevention through to long-term condition management. What is the role of community pharmacy and how do we guide people to seek support from the most appropriate healthcare professional? What is the vision for community pharmacy delivering patient care in the next decade? The lesson from Scotland is that the government needs to sit down with the sector and map that out together. There are no quick fix overnight solutions. This needs to be a long-term commitment backed by adequate funding. Supervision regulations need to change and there needs to be a thought through workforce strategy which avoids community pharmacy shortages as that does nothing to deliver improved patient outcomes.

Atorvastatin, a medicine to treat high blood cholesterol, is the most dispensed drug with 59 million items in England in 2022/23, revealed the NHS Business Services Authority (NHSBSA) on Thursday (8 June). While Apixaban (an anticoagulant) was the drug with the highest costs of £430 million. Apixaban 5mg tablets had the largest increase in cost between 2021/22 and 2022/23 in England, with an increase of £280 million. NHSBSA's annual statistics report 'Prescription Cost Analysis-England 2022/23' published also has revealed an eight per cent rise in the prescription items that were dispensed in the community in England. The report highlighted that in 2022/23, 1.18 billion prescription items were dispensed at a cost of £10.4 billion in the community in England, witnessing an increase of eight per cent from £9.69 billion in 2021/22.

Instability in the supply chain network is frequently undermining the profit margins in community pharmacies, former Pharmacy Minister and Chair of the Health and Social Care Committee Steve Brine has said. Brine emphasised that community pharmacies often lack information about the prices wholesalers charge for essential generic medications. "They lack visibility into scarcity, and the pricing of these products is often significantly higher compared to other European countries," the former minister remarked during a parliamentary debate focused on the future of community pharmacies on September 14. From financial pressures to workforce crisis and pharmacy closures, the debate delved into critical challenges faced by pharmacies, aiming to propose tangible solutions for a sustainable future in the sector. Chaired by Sir Mark Hendrik, the debate was initiated by Conservative MP Peter Aldous and featured contributions from a host of participants including Labour MPs Taiwo Owatemi and George Howarth among others.

A new report commissioned by the National Pharmacy Association (NPA) has revealed harsh financial realities faced by community pharmacies in England. The report by Professor David Taylor of University College London warned that 1000s of community pharmacy closure might take place by 2024 in England if the sector was not supported with additional funds. At the launch of the report titled 'Protecting UK Public Interests in NHS Community Pharmacy', Prof Taylor said: "There will be several 1,000s of closures over the next few years unless we take appropriate action, which doesn't mean to pour money all over it, but it is to fund appropriately when necessary. "At the moment, if we got a partial collapse in the pharmacy network it would disrupt medicine supply and increase health inequalities… For me, it's missing out on the future development of better and more accessible care, which would be the tragedy of reducing, harming and damaging the pharmacy network unnecessarily."

The trade bodies and four largest pharmacy chains in England, have jointly written to the Secretary of State for Health, Steve Barclay, warning that the sector needs urgent investment for sustainability. The letter from AIMp, CCA, NPA, PSNC, Boots UK, Lloyds Pharmacy, Well, and Phoenix UK, warned that the 30 per cent real terms funding cuts that pharmacies have faced over the past seven years have left many businesses in a cashflow crisis. The letter said that the government is facing a choice over the future of the country's 11,000+ community pharmacies, with permanent closures likely and medicines supply at risk if no urgent action is taken. "If the funding situation is not addressed, the sector is likely to move rapidly towards many permanent closures of pharmacies." The organisations say that once these closures start, they will be hard to stop, as the sector is now so fragile other pharmacies would struggle to pick up the slack.

The Royal Pharmaceutical Society (RPS) has called pharmacy employers and pharmacy trade unions to come together to a round table meeting to agree on principles for a way forward that ensures patients benefit consistently from access to high quality, adequately staffed, safe pharmacy services. It has also urged the governments, NHS organisations and individual pharmacy teams to define clear prioritisation plans, which can be embedded in organisational business continuity plans which set out the pharmacy services that are essential and must always be provided and can be de-prioritised at specific levels of pressures. The challenges for pharmacies are compounded by the escalating cost of living crisis. With unprecedented levels of burnout among pharmacists, pharmacy closures and the potential for strike action, RPS has called for three things- 'professionalism, respect and prioritisation.'

The Pharmacy First service, set for launch in England at the end of January, is expected to help reduce some of the pressure on the National Health Service (NHS). But the question is - Are pharmacists ready to take the extra workload amidst many issues community pharmacies are currently facing? Nearly 50 per cent of pharmacy workers surveyed by ITV News said they do not feel confident they can provide the new services. Pharmacy leaders told the British news channel that the industry is already in crisis, and they are facing a "potentially fatal cocktail" of rising prices, major supply problems and a lack of funding.

Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry, which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK. The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout each module. A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am. NPA calls for funding to boost pharmacy resilience Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.

As Prime Minister Rishi Sunak announces the forthcoming UK general election, pharmacy bodies are calling on all political parties to commit to solving the issues facing the sector. The next UK general election will be held on 4 July, Sunak announced it on Wednesday afternoon during a press conference outside 10 Downing Street. "As the election is called it's imperative that any incoming government addresses the crisis in primary care and the looming cliff edge facing pharmacies, which for millions of people are the front door to the NHS and a crucial source of frontline health care," said Paul Rees, Chief Executive of the National Pharmacy Association (NPA). Noting that the first responsibility of the government is to keep its people safe and healthy, he emphasised the importance of addressing the "deep funding gap that is pushing record numbers of pharmacies to the edge of closure and beyond, exacerbating the issues of waiting lists for GPs and hospital care."